IDEXX Laboratories, Inc. vs JPMorgan Equity Premium Income ETF — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while JPMorgan Equity Premium Income ETF trades at $56.56. The key difference: JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | JEPI | |
|---|---|---|
Market Cap | $44.48B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $59.88 |
52-Week Low | $520.87 | $55.29 |
Enterprise Value | $45.38B | — |
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
JEPI trades at $56.39, down 0.28% on the day, with technical indicators showing a bearish trend from moving averages while oscillators remain neutral. The ETF's covered call strategy generates high income but has underperformed the S&P 500 due to sector underweighting and upside caps. Recent news highlights tax inefficiencies and competition from alternatives like SPYI and DIVO.
JEPI's 8% yield appeals to income-focused investors, but total return potential is limited in bull markets. Risks include tracking error, tax disadvantages in taxable accounts, and sector concentration. Analyst sentiment is mixed, with some favoring more dynamic covered-call ETFs for better risk-adjusted returns in current market conditions.
Trailing returns across standard periods
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →